// App-Quantinova.ai

TCT-176 : Implantation of Thin-Strut Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With De Novo Coronary Artery Lesions: 2-Year Clinical and 6-Month Imaging Outcomes of the MeRes-1 Extend Trial

Researchers

Presenter

  • Alexandre Abizaid

Principal Investigators

  • Sasko Kedev

  • Rosli Bin Mohd Ali

  • Teguh Santoso

  • Angel Cequier

  • R.J.M. Van Geuns

  • Bernard Chevalier

  • Farrel Hellig

  • Ricardo Costa

  • Yoshinobu Onuma

  • J. Ribamar Costa Jr.

  • Patrick Serruys

  • Sripal Bangalore

Medical Centers

  • National Heart Institute, Kuala Lumpur, Malaysia

  • Thoraxcenter Erasmus Medical Center, Rotterdam, the Netherlands

  • Sunninghill Hospital /University of Cape Town, Johannesburg, South Africa

  • Medistra Hospital, Jakarta, Indonesia

  • Imperial College, London, United Kingdom

  • Ramsay Générale de Santé, Institut Cardiovasculaire Paris-Sud, Massy, France

  • Bellvitge University Hospital, Barcelona, Spain

  • Instituto Dante Pazzanese de Cardiologia, São Paulo, São Paulo, Brazil

  • University Clinic of Cardiology, Skopje, Macedonia, the former Republic of Yugoslav

  • New York University School of Medicine, New York, New York, USA

Locations

  • Malaysia

  • Macedonia

  • Brazil

  • Spain

  • France

  • United Kingdom

  • Indonesia

  • South Africa

  • Netherlands

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Cardiovascular (CVS)

Disease

  • Coronary artery lesions

  • Myocardial infarction

  • Coronary Artery Disease

Biomarkers

  • N/A

Drug/Treatment

  • sirolimus

  • Rapacan

Outcome

  • N/A

Study Design

  • Single Arm

  • Multicenteric

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved